v3.20.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Schedule of worldwide net revenues
AbbVie operates in one business segment—pharmaceutical products. The following table details AbbVie’s worldwide net revenues:
 
 
Three months ended
March 31,
 
 
(in millions)
 
2020
 
2019
Immunology
 
 
 
HUMIRA
United States
$
3,656

 
$
3,215

 
International
1,047

 
1,231

 
Total
$
4,703

 
$
4,446

SKYRIZI
United States
$
266

 
$
—

 
International
34

 
—

 
Total
$
300

 
$
—

RINVOQ
United States
$
82

 
$
—

 
International
4

 
—

 
Total
$
86

 
$
—

Hematologic Oncology
 
 
 
IMBRUVICA
United States
$
966

 
$
829

 
Collaboration revenues
266

 
193

 
Total
$
1,232

 
$
1,022

VENCLEXTA
United States
$
201

 
$
105

 
International
116

 
46

 
Total
$
317

 
$
151

HCV
 
 
 
MAVYRET
United States
$
234

 
$
403

 
International
325

 
387

 
Total
$
559

 
$
790

VIEKIRA
International
$
5

 
$
25

Other Key Products
 
 
 
Creon
United States
$
276

 
$
227

Lupron
United States
$
195

 
$
191

 
International
38

 
38

 
Total
$
233

 
$
229

Synthroid
United States
$
205

 
$
182

Synagis
International
$
270

 
$
287

Duodopa
United States
$
25

 
$
22

 
International
99

 
89

 
Total
$
124

 
$
111

Sevoflurane
United States
$
16

 
$
17

 
International
63

 
75

 
Total
$
79

 
$
92

Kaletra
United States
$
14

 
$
13

 
International
72

 
65

 
Total
$
86

 
$
78

ORILISSA
United States
$
30

 
$
13

 
International
1

 
—

 
Total
$
31

 
$
13

AndroGel
United States
$
8

 
$
74

All other
 
$
105

 
$
101

Total net revenues
$
8,619

 
$
7,828